Search research articles
Contact Us
Filters
Showing results (41-50 of 82) with videos related to
Page
of 9
Sort By:
Circulation
|
August 20, 2003
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial
Christopher B Granger, Kenneth W Mahaffey, W Douglas Weaver, et al.
Circulation. Cardiovascular Quality and Outcomes
|
February 10, 2011
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial
Michael P Hudson, Paul W Armstrong, William W O'Neil, et al.
Journal of the American College of Cardiology
|
May 10, 2008
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both
L Michael Prisant, Kevin L Thomas, Eldrin F Lewis, et al.
Circulation
|
August 20, 2003
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial
Kenneth W Mahaffey, Christopher B Granger, Jose C Nicolau, et al.
Circulation. Cardiovascular Quality and Outcomes
|
May 17, 2012
Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights
Sean van Diepen, Petr Widimsky, Renato D Lopes, et al.
American Heart Journal
|
December 13, 2005
Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials
Camille G Frazier, Svati H Shah, Paul W Armstrong, et al.
European Heart Journal
|
June 9, 2009
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial
Renato D Lopes, Laine E Elliott, Harvey D White, et al.
Clinical Cardiology
|
October 10, 2019
Interleukin-18 in patients with acute coronary syndromes
Axel Åkerblom, Stefan K James, Tatevik G Lakic, et al.
The American Journal of Cardiology
|
February 5, 2003
Time-dependent predictors of primary cardiac arrest in patients with acute myocardial infarction
Harry P Selker, Merritt H Raitt, Christopher H Schmid, et al.
Journal of the American Heart Association
|
October 26, 2017
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
Claes Held, Harvey D White, Ralph A H Stewart, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 82) with videos related to
Sort By:
Page
of 9
Circulation
|
August 20, 2003
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial
Christopher B Granger, Kenneth W Mahaffey, W Douglas Weaver, et al.
Circulation. Cardiovascular Quality and Outcomes
|
February 10, 2011
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial
Michael P Hudson, Paul W Armstrong, William W O'Neil, et al.
Journal of the American College of Cardiology
|
May 10, 2008
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both
L Michael Prisant, Kevin L Thomas, Eldrin F Lewis, et al.
Circulation
|
August 20, 2003
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial
Kenneth W Mahaffey, Christopher B Granger, Jose C Nicolau, et al.
Circulation. Cardiovascular Quality and Outcomes
|
May 17, 2012
Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights
Sean van Diepen, Petr Widimsky, Renato D Lopes, et al.
American Heart Journal
|
December 13, 2005
Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials
Camille G Frazier, Svati H Shah, Paul W Armstrong, et al.
European Heart Journal
|
June 9, 2009
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial
Renato D Lopes, Laine E Elliott, Harvey D White, et al.
Clinical Cardiology
|
October 10, 2019
Interleukin-18 in patients with acute coronary syndromes
Axel Åkerblom, Stefan K James, Tatevik G Lakic, et al.
The American Journal of Cardiology
|
February 5, 2003
Time-dependent predictors of primary cardiac arrest in patients with acute myocardial infarction
Harry P Selker, Merritt H Raitt, Christopher H Schmid, et al.
Journal of the American Heart Association
|
October 26, 2017
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
Claes Held, Harvey D White, Ralph A H Stewart, et al.
Page
of 9